Cancer Family
Adnexal Neoplasm
CI-CAN-00000005Explore in graph →
Non-malignant776 active trials5 approved drugs94 evidence items
- NCIt
- C212119
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000005Explore in graph →
Clinical trials
3,521 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03740165 | Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) | completed | Phase 3 | 1,367 | Merck Sharp & Dohme LLCINDUSTRY | 22 | Aug 19, 2026 | clinicaltrials |
| NCT02101788 | Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer | completed | Phase 2 / Phase 3 | 260 | National Cancer Institute (NCI)NIH |
| 2 |
| Aug 4, 2026 |
| clinicaltrials |
| NCT00951496 | Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 3 | 1,560 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2026 | clinicaltrials |
| NCT06007586 | Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients | completed | Phase 3 | 143 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT04908787 | A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer | completed | Phase 3 | 421 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 11, 2025 | clinicaltrials |
| NCT04534075 | Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial(FIDURA) | completed | Phase 3 | 354 | Sahlgrenska University HospitalOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT03534453 | Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy(L-MOCA) | completed | Phase 3 | 229 | AstraZenecaINDUSTRY | 2 | Jul 10, 2025 | clinicaltrials |
| NCT03863860 | A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients | completed | Phase 3 | 252 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 3, 2025 | clinicaltrials |
| NCT03353831 | Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer | completed | Phase 3 | 574 | AGO Research GmbHINDUSTRY | 12 | Apr 6, 2025 | clinicaltrials |
| NCT02891824 | ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab(ATALANTE) | completed | Phase 3 | 614 | ARCAGY/ GINECO GROUPOTHER | 7 | Feb 11, 2025 | clinicaltrials |
| NCT04227522 | Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients(MAMOC) | completed | Phase 3 | 42 | North Eastern German Society of Gynaecological OncologyOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT03635489 | A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 3 | 100 | Hoffmann-La RocheINDUSTRY | 1 | Oct 3, 2024 | clinicaltrials |
| NCT03598270 | Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer(ANITA) | completed | Phase 3 | 417 | Grupo Español de Investigación en Cáncer de OvarioOTHER | 5 | Aug 30, 2024 | clinicaltrials |
| NCT03402841 | Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients(OPINION) | completed | Phase 3 | 279 | AstraZenecaINDUSTRY | 19 | Aug 21, 2024 | clinicaltrials |
| NCT04296890 | A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression(SORAYA) | completed | Phase 3 | 106 | ImmunoGen, Inc.INDUSTRY | 11 | Aug 7, 2024 | clinicaltrials |
| NCT04676334 | CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib(CATCH-R) | completed | Phase 3 | 34 | pharmaand GmbHINDUSTRY | 6 | May 7, 2024 | clinicaltrials |
| NCT03940196 | Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3) | completed | Phase 3 | 540 | NovoCure Ltd.INDUSTRY | 13 | Mar 29, 2024 | clinicaltrials |
| NCT00716976 | Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy | completed | Phase 3 | 131 | Children's Oncology GroupNETWORK | 3 | Nov 9, 2023 | clinicaltrials |
| NCT01506856 | Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial(iPocc) | completed | Phase 2 / Phase 3 | 655 | Gynecologic Oncology Trial & Investigation ConsortiumNETWORK | 6 | Sep 15, 2023 | clinicaltrials |
| NCT01968213 | Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)(ARIEL3) | completed | Phase 3 | 564 | pharmaand GmbHINDUSTRY | 11 | Jun 9, 2023 | clinicaltrials |
| NCT02855944 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | completed | Phase 3 | 349 | pharmaand GmbHINDUSTRY | 12 | Jun 9, 2023 | clinicaltrials |
| NCT01847274 | A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer | completed | Phase 3 | 596 | Tesaro, Inc.INDUSTRY | 15 | Jun 2, 2023 | clinicaltrials |
| NCT03038100 | A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer(IMagyn050) | completed | Phase 3 | 1,301 | Hoffmann-La RocheINDUSTRY | 22 | Feb 17, 2023 | clinicaltrials |
| NCT03398655 | A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)(OVAL) | completed | Phase 3 | 408 | Vascular Biogenics Ltd. operating as VBL TherapeuticsINDUSTRY | 5 | Jan 10, 2023 | clinicaltrials |
| NCT03106987 | A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.(OReO) | completed | Phase 3 | 220 | AstraZenecaINDUSTRY | 11 | Oct 7, 2022 | clinicaltrials |
| NCT02477644 | Platine, Avastin and OLAparib in 1st Line(PAOLA-1) | completed | Phase 3 | 806 | Arcagy ResearchOTHER | 11 | Aug 2, 2022 | clinicaltrials |
| NCT01462890 | Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer(BOOST) | completed | Phase 3 | 927 | AGO Study GroupOTHER | 6 | Jul 20, 2022 | clinicaltrials |
| NCT00976911 | AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer | completed | Phase 3 | 361 | Hoffmann-La RocheINDUSTRY | 14 | Jun 21, 2022 | clinicaltrials |
| NCT01379989 | INOVATYON STUDY -International, Randomized Study in Patients With Ovarian Cancer(INOVATYON) | completed | Phase 3 | 617 | Mario Negri Institute for Pharmacological ResearchOTHER | 11 | Feb 9, 2022 | clinicaltrials |
| NCT03180307 | OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer | completed | Phase 3 | 140 | On Target Laboratories, LLCINDUSTRY | 2 | Feb 4, 2022 | clinicaltrials |
| NCT02903004 | Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients(MITO23) | completed | Phase 3 | 242 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 25, 2021 | clinicaltrials |
| NCT00053352 | Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors | completed | Phase 3 | 302 | Children's Oncology GroupNETWORK | 6 | Jul 13, 2021 | clinicaltrials |
| NCT01837251 | Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer | completed | Phase 3 | 682 | AGO Research GmbHINDUSTRY | 6 | Jul 13, 2021 | clinicaltrials |
| NCT00866697 | Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 3 | 940 | Novartis PharmaceuticalsINDUSTRY | 17 | Feb 16, 2021 | clinicaltrials |
| NCT00262990 | Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer | completed | Phase 3 | 829 | Novartis PharmaceuticalsINDUSTRY | 12 | Dec 17, 2020 | clinicaltrials |
| NCT02490488 | Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients | completed | Phase 2 / Phase 3 | 248 | AB ScienceINDUSTRY | 6 | Dec 8, 2020 | clinicaltrials |
| NCT01461850 | Surgical Complications Related to Primary or Interval Debulking in Ovarian Neoplasm(SCORPION) | completed | Phase 3 | 171 | Catholic University of the Sacred HeartOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT02631876 | A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer(FORWARD I) | completed | Phase 3 | 366 | ImmunoGen, Inc.INDUSTRY | 13 | Oct 14, 2020 | clinicaltrials |
| NCT04237090 | Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel(PREMED-F1) | completed | Phase 3 | 27 | Ciusss de L'Est de l'Île de MontréalOTHER | 1 | Oct 12, 2020 | clinicaltrials |
| NCT02421588 | Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients(CORAIL) | completed | Phase 3 | 442 | PharmaMarINDUSTRY | 1 | Apr 3, 2020 | clinicaltrials |
| NCT00028743 | Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | completed | Phase 3 | 819 | NCIC Clinical Trials GroupNETWORK | 1 | Apr 2, 2020 | clinicaltrials |
| NCT00477282 | Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer | completed | Phase 3 | 509 | BioNumerik Pharmaceuticals, Inc.INDUSTRY | 5 | Mar 12, 2020 | clinicaltrials |
| NCT00226915 | Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma | completed | Phase 3 | 637 | Japanese Gynecologic Oncology GroupOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT01091636 | Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Ovarian Cancer | completed | Phase 2 / Phase 3 | 184 | National Cancer Center, KoreaOTHER_GOV | 1 | Feb 17, 2020 | clinicaltrials |
| NCT00001806 | Methods in Education for Breast Cancer Genetics | completed | Phase 3 | 170 | National Cancer Institute (NCI)NIH | 1 | Dec 12, 2019 | clinicaltrials |
| NCT00041080 | Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 3 | 139 | National Cancer Institute (NCI)NIH | 1 | Jul 30, 2019 | clinicaltrials |
| NCT00262847 | Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 3 | 1,873 | National Cancer Institute (NCI)NIH | 4 | Jul 23, 2019 | clinicaltrials |
Data updated 22 days agoSource updated Aug 19, 2026source: clinicaltrials